Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01828-20.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses to the spike (S) protein monomer, S protein native trimeric form, or the nucleocapsid (N) proteins were evaluated in cohorts of individuals with acute infection ( = 93) and in individuals enrolled in a postinfection seroprevalence population study ( = 578) in Switzerland. Commercial assays specific for the S1 monomer, for the N protein, or within a newly developed Luminex assay using the S protein trimer were found to be equally sensitive in antibody detection in the acute-infection-phase samples. Interestingly, compared to anti-S antibody responses, those against the N protein appear to wane in the postinfection cohort. Seroprevalence in a "positive patient contacts" group ( = 177) was underestimated by N protein assays by 10.9 to 32.2%, while the "randomly selected" general population group ( = 311) was reduced by up to 45% relative to the S protein assays. The overall reduction in seroprevalence targeting only anti-N antibodies for the total cohort ranged from 9.4 to 31%. Of note, the use of the S protein in its native trimer form was significantly more sensitive compared to monomeric S proteins. These results indicate that the assessment of anti-S IgG antibody responses against the native trimeric S protein should be implemented to estimate SARS-CoV-2 infections in population-based seroprevalence studies. In the present study, we have determined SARS-CoV-2-specific antibody responses in sera of acute and postinfection phase subjects. Our results indicate that antibody responses against viral S and N proteins were equally sensitive in the acute phase of infection, but that responses against N appear to wane in the postinfection phase where those against the S protein persist over time. The most sensitive serological assay in both acute and postinfection phases used the native S protein trimer as the binding antigen, which has significantly greater conformational epitopes for antibody binding compared to the S1 monomer protein used in other assays. We believe these results are extremely important in order to generate correct estimates of SARS-CoV-2 infections in the general population. Furthermore, the assessment of antibody responses against the trimeric S protein will be critical to evaluate the durability of the antibody response and for the characterization of a vaccine-induced antibody response.
评估了严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)特异性抗体对刺突(S)蛋白单体、S 蛋白天然三聚体形式或核衣壳(N)蛋白的反应,这些反应存在于急性感染个体的队列中( = 93)和瑞士感染后血清流行率人群研究中的个体中( = 578)。发现针对 S1 单体、N 蛋白的商业检测试剂盒或使用 S 蛋白三聚体的新开发的 Luminex 检测试剂盒在急性感染期样本中的抗体检测中同样敏感。有趣的是,与抗-S 抗体反应相比,那些针对 N 蛋白的反应似乎在感染后队列中减弱。与 S 蛋白检测相比,N 蛋白检测在“阳性患者接触者”组( = 177)中低估了血清阳性率 10.9%至 32.2%,而“随机选择”的一般人群组( = 311)的血清阳性率降低了 45%。针对总队列,仅针对抗-N 抗体的血清阳性率总体降低幅度为 9.4%至 31%。值得注意的是,天然三聚体形式的 S 蛋白的使用明显比单体 S 蛋白更敏感。这些结果表明,应该实施针对天然三聚体 S 蛋白的抗-S IgG 抗体反应的评估,以估计基于人群的血清流行率研究中的 SARS-CoV-2 感染。在本研究中,我们确定了急性和感染后阶段受试者血清中的 SARS-CoV-2 特异性抗体反应。我们的结果表明,在感染的急性期,针对病毒 S 和 N 蛋白的抗体反应同样敏感,但针对 N 的反应似乎在感染后阶段减弱,而针对 S 蛋白的反应则随着时间的推移持续存在。在急性和感染后阶段最敏感的血清学检测使用天然 S 蛋白三聚体作为结合抗原,与其他检测中使用的 S1 单体蛋白相比,它具有显著更多的抗体结合构象表位。我们认为这些结果对于正确估计普通人群中的 SARS-CoV-2 感染非常重要。此外,对三聚体 S 蛋白的抗体反应评估将是评估抗体反应持久性和表征疫苗诱导的抗体反应的关键。
Microbiol Spectr. 2021-10-31
Microbiol Spectr. 2021-10-31
Microbiol Spectr. 2021-10-31
Microbiol Spectr. 2021-10-31
Commun Med (Lond). 2024-11-30
Epidemiol Psychiatr Sci. 2024-11-28
BMC Public Health. 2024-11-2
J Clin Virol. 2021-1
Emerg Microbes Infect. 2020-12
J Clin Virol. 2020-6-1
Nat Med. 2020-5-7
Nat Med. 2020-6